Disseminated Bacillus Calmette-Guerin infection following concurrent intravesical BCG therapy and immune checkpoint inhibitior therapy: a case report.
증례보고
1/5 보강
[UNLABELLED] Disseminated Bacillus Calmette-Guérin (BCG) infection is a rare complication of intravesical BCG therapy, affecting both immunocompetent and immunocompromised patients.
APA
Plymoth M, C CW, et al. (2025). Disseminated Bacillus Calmette-Guerin infection following concurrent intravesical BCG therapy and immune checkpoint inhibitior therapy: a case report.. BMC infectious diseases, 25(1), 1575. https://doi.org/10.1186/s12879-025-11511-3
MLA
Plymoth M, et al.. "Disseminated Bacillus Calmette-Guerin infection following concurrent intravesical BCG therapy and immune checkpoint inhibitior therapy: a case report.." BMC infectious diseases, vol. 25, no. 1, 2025, pp. 1575.
PMID
41233774 ↗
Abstract 한글 요약
[UNLABELLED] Disseminated Bacillus Calmette-Guérin (BCG) infection is a rare complication of intravesical BCG therapy, affecting both immunocompetent and immunocompromised patients. We present a case of disseminated BCG infection in an 86-year-old man undergoing immune checkpoint inhibitor therapy for relapsed Hodgkin lymphoma and concomitant intravesical BCG therapy for non-muscle-invasive bladder cancer. The patient developed a progressive mycotic abdominal aortic aneurysm, psoas abscess, and vertebral osteomyelitis. BCG was confirmed via Polymerase Chain Reaction (PCR) and mycobacterial culture from a psoas abscess biopsy. Despite appropriate antimycobacterial therapy and multiple attempts at abscess drainage, his condition deteriorated, ultimately leading to his death. This case highlights the challenges of diagnosing disseminated BCG infection, which can mimic malignancy, and suggests a possible link between immune checkpoint inhibitors and BCG dissemination. Clinicians should maintain a high index of suspicion for BCG-related complications, particularly among those receiving immune-modulating therapies.
[SUPPLEMENTARY INFORMATION] The online version contains supplementary material available at 10.1186/s12879-025-11511-3.
[SUPPLEMENTARY INFORMATION] The online version contains supplementary material available at 10.1186/s12879-025-11511-3.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Immune checkpoint inhibitors in BCG-unresponsive non-muscle-invasive bladder cancer: a narrative review of evidence and future directions.
- Dapsone-induced methemoglobinemia in gynecologic cancer patients treated with immune checkpoint Inhibitors: a case series.
- Patient-Reported Symptom and Symptom Clusters During Immune Checkpoint Inhibitor Therapy for Cancer Patients: A Cross-Sectional Survey.
- Recent Advances in Immunotherapy for Non-Muscle-Invasive Bladder Cancer.
- [Gender-specific differences in outcome and survival in early cystectomy : Systematic review].
- The potential antitumor effects of combining intravesical therapy with recombinant bacillus calmette-guérin and an anti-PD-1 inhibitor in bladder cancer.